INDICATIONS AND USAGE（适应症）

Hepatocellular Carcinoma

NEXAVAR® is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC).

Renal Cell Carcinoma

NEXAVAR is indicated for the treatment of patients with advanced renal cell carcinoma (RCC).

Differentiated Thyroid Carcinoma

NEXAVAR is indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.

DOSAGE（服用剂量）

The recommended dosage of NEXAVAR is 400 mg orally twice daily without food (at least 1 hour before or 2 hours after a meal) until the patient is no longer clinically benfiting from therapy or until unacceptable toxicity.

ADVERSE REACTIONS（不良反应）

The following clinically significant adverse reactions are discussed elsewhere in the labeling:

Cardiovascular events

Hemorrhage

Hypertension

Dermatologic toxicities

Gastrointestinal perforation

QT interval prolongation

Drug-induced liver injury

Impairment of TSH suppression in DTC

For full information, please refer to:

https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/b50667e4-5ebc-4968-a646-d605058dbef0/spl-doc?hl=Sorafenib

Sorafenatinformation